Fundraising Fox
Immunitoai
Entrepreneur First '21Bangalore, IN · Founded 2021 · 25 employees on LinkedIn · 10 known investors
Find your way into Immunitoai
Sign up to see every warm intro you have to Immunitoai
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Immunitoai team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Immunito AI is an in-silico antibody discovery company that combines artificial intelligence with an in-house biological lab to speed up and improve the discovery of antibodies. It serves the biotech and biopharmaceutical industry.
Also known as Immunito AI · immunitoAI
Founders & leadership
Immunitoai was founded in 2021 by Trisha Chatterjee and Aridni Shah.
Investors · 10
How we know: the Entrepreneur First portfolio · economictimes.indiatimes.com · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: pi Ventures's portfolio page · ipocentral.in · the VCSheet dataset · Not right? Tell us
How we know: ipocentral.in · Not right? Tell us
How we know: ipocentral.in · Not right? Tell us
Also in the syndicate · 5
Funding
SEC filings, press & company announcements$6.1M disclosed across 1 of 2 rounds · 2025–2026
- Undisclosed amountseed fundingJan 2026
pi Ventures (lead), Entrepreneur First
Source ↗ - $6.1MSeries ANov 2025 · 3 sources
Ashish Kacholia (lead), 3one4 Capital, AC Ventures, Anicut Capital, JITO Incubation & Innovation Foundation, JJ Family, JJ Family Office, LVX, pi Ventures
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Company profile
researched Aug 2026Immunito AI (immunitoai.com) is an antibody discovery company founded in 2021 and headquartered in Bangalore, India. It applies computational, artificial-intelligence-based methods to the design of antibodies, operating an in-house biological laboratory alongside its software work so that computationally generated candidates can be produced and evaluated experimentally.
The company's platform is described as generating novel antibody sequences optimized for target binding, specificity, and developability. Researchers specify a disease target and receive candidate molecules generated in silico, which is intended to shorten lead discovery timelines and reduce the amount of laboratory screening required. No independent public source documents were available at the time of compilation, so the profile rests on internally held information only.
Founding story
The company was founded in 2021 by Aridni Shah and Trisha Chatterjee, who serve as CEO and CTO respectively. Dr. Abhishek Mathur is also associated with the company. Further details of the founding are not available in the material reviewed.
Business model
Immunito AI positions itself as a discovery partner to organizations developing antibody therapeutics, supplying computationally designed antibody candidates supported by in-house wet-lab capability. No pricing, contracting, or revenue-model details are available from the material reviewed.
Latest developments
No dated public developments could be verified; no fetchable web sources were available at the time of compilation.
▸Full profile — market position, technology, go-to-market, geography
Market position
Immunito AI is an early-stage company in the AI-enabled antibody discovery segment; no market share, ranking, or comparative performance data is available in the material reviewed.
Technology
An in-silico antibody design platform that uses artificial intelligence to generate novel antibody sequences optimized for target binding, specificity, and developability, coupled with an in-house biological laboratory used in the discovery workflow.
Go-to-market
Biotech and biopharmaceutical organizations pursuing antibody-based therapeutics, and researchers who supply disease targets for candidate generation.
Geography
Headquartered in Bangalore, India.
Related companies · 2
Companies working in the same space as Immunitoai.
Frequently asked questions
- What does Immunitoai do?
- Bangalore-based in-silico antibody discovery company pairing AI-driven design with an in-house biology lab.
- Who founded Immunitoai?
- Immunitoai was founded by Trisha Chatterjee, Aridni Shah in 2021.
- Who are Immunitoai's investors?
- Immunitoai's investors include Entrepreneur First, pi Ventures, 3one4 Capital, AC Ventures, Anicut Capital.
- How much funding has Immunitoai raised?
- Immunitoai has disclosed $6.1M raised across 1 of its 2 known rounds.
- Where is Immunitoai headquartered?
- Immunitoai is headquartered in Bangalore, IN.